.png){kind=icon}
.png){kind=icon}
Return
Dissecting divergent outcomes in stem cell-derived dopamine cell therapy trials for Parkinson’s disease
.png){kind=icon}
OA
AI
C
S
S
P
D
DOI：10.1016/j.stem.2026.07.002.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Fetal tissue transplantation established proof-of-concept for dopamine cell replacement in Parkinson’s disease but yielded inconsistent outcomes due to limited tissue availability and cellular heterogeneity. Advances in generating high-purity dopamine progenitors from pluripotent stem cells have enabled standardized products that show safety and motor improvement in clinical trials. However, these trials revealed divergent outcomes arising at three levels: between clinical studies, driven by differences in cell products, baseline patient characteristics, or immunosuppressants; between patients, influenced by alloimmune factors, genetic background, or co-pathology; and within patients, where graft survival varies across transplantation sites due to the local microenvironment or surgical technique.
Keywords:
human pluripotent stem cells
high-purity dopamine progenitors
Parkinson’s disease
dopaminergic cell therapy
clinical trial
Journal
IF:
20.4
Papers:
3.6K
Citations:
3.1W
Organization
Cited Papers